Gordeev A V, Galushko E A, Savushkina N M
Nasonova Research Institute of Rheumatology.
Ter Arkh. 2021 May 15;93(5):635-639. doi: 10.26442/00403660.2021.05.200796.
The significant humoral effect of the renin-angiotensin-aldosterone system on the regulation of the cardiovascular system and blood pressure has long been widely known. However, the identification and interpretation of new components of renin-angiotensin-aldosterone system in recent years can significantly expand the range of its potential effects on the body. The anti-inflammatory effect of drugs that block angiotensin II and its receptors, including in rheumatic diseases, can become practically significant for General therapists by their effect on reducing the concentration of inflammatory mediators and angiogenesis processes. The organoprotective and anti-inflammatory potentials of drugs that reduce the production of at demonstrated in vitro and in vivo experiments allow us to consider them as first-line angiotropic agents in patients with rheumatoid arthritis, especially in the presence of pathology of the cardiovascular system and kidneys.
肾素-血管紧张素-醛固酮系统对心血管系统和血压调节具有显著的体液效应,这一点早已广为人知。然而,近年来对肾素-血管紧张素-醛固酮系统新成分的识别和解读,可显著拓展其对机体潜在作用的范围。阻断血管紧张素II及其受体的药物的抗炎作用,包括在风湿性疾病中的作用,通过其对降低炎症介质浓度和血管生成过程的影响,对全科医生而言可能具有实际意义。在体外和体内实验中证实的减少醛固酮生成的药物的器官保护和抗炎潜力,使我们有理由将它们视为类风湿关节炎患者,尤其是存在心血管系统和肾脏病变患者的一线血管靶向药物。